Eosinophilic Myocarditis in a Patient with Multiple Myeloma

Publication date: Available online 8 April 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Gabriela Sanchez-Petitto, Naomi Hardy, Allen Burke, Michael G. McCusker, Andrew Li, Ashraf Z. Badros
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Condition:   Relapsed / Refractory Mantle Cell Lymphoma (MCL) Intervention:   Drug: TQ-B3525 Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Leukemia, Lymphoblastic Intervention:   Behavioral: ETOILE therapeutic education Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Lymphoblastic Leukemia, Pediatric;   Pediatric Cancer Interventions:   Behavioral: Active Music Engagement;   Behavioral: Audio Storybooks Sponsors:   Indiana University;   Children's Mercy Hospital Kansas City;   Ann&Robert H Lurie Children's Hospital of Chicago;   Riley Children's Health Indiana University Health Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Lymphoma, Large B-Cell, Diffuse Intervention:   Biological: Nonconforming Lisocabtagene Maraleucel Sponsor:   Juno Therapeutics, a Subsidiary of Celgene Temporarily not available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Contributors : Junke Zheng ; Chiqi ChenSeries Type : Expression profiling by arrayOrganism : Mus musculusTo dissect the metabolic state of B-ALL cells, we have developed a genetically encoded fluorescent sensor (SoNar) for tracking cytosolic NADH and NAD+ redox states and constructed the transgenic mouse. Based on the NADH/NAD+ ratio, we have sorted SoNar-high and SoNar-low B-ALL cells to employ whole genome microarray expression profiling as a discovery platform to identify genes with the potential to regulate the metabolism of B-ALL cells.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
Contributors : Anuhar Chaturvedi ; Razif Gabdoulline ; Michael HeuserSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMutations in the enzymes IDH1 and IDH2 have been identified in a wide variety of tumors like glioma, chondrosarcoma, thyroid cancer, lymphoma, melanoma, and in acute myeloid leukemia. Mutated IDH1/2 produces the metabolite 2-hydroxyglutarate (2HG), which interferes with epigenetic regulation of gene expression, and thus may promote tumorigenesis. Data for IDH1 inhibitors show that 30-40% of AML patients respond to monotherapy with a median duration of response of 8 mont...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Contributors : Anuhar Chaturvedi ; Razif Gabdoulline ; Michael HeuserSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensMutations in the enzymes IDH1 and IDH2 have been identified in a wide variety of tumors like glioma, chondrosarcoma, thyroid cancer, lymphoma, melanoma, and in acute myeloid leukemia. Mutated IDH1/2 produces the metabolite 2-hydroxyglutarate (2HG), which interferes with epigenetic regulation of gene expression, and thus may promote tumorigenesis. Data for IDH1 inhibitors show that 30-40% of AML patients respond to monotherapy with a median duration of response of 8 months, su...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Methylation profiling by genome tiling array Homo sapiens Source Type: research
Publication date: Available online 24 May 2020Source: European Journal of Integrative MedicineAuthor(s): Inès Limam, Mohamed Abdelkarim, Rym Essid, Ahlem Chahbi, Mayssa Fathallah, Salem Elkahoui, Fatma Ben Aissa-Fennira
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
Conclusions: Tislelizumab or Camrelizumab could be a new treatment option for patients with relapsed or refractory classical Hodgkin lymphoma in China. Three-month 18F-FDG PET/CT scans detected HL patients responding to anti-PD1. New patterns were encountered in 15% of patients, emphasizing the need for further evaluation in larger series and close collaboration between imaging and oncology specialists on a per-patient basis.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Lymphoma / Leukemia / Myeloma Posters Source Type: research
INTRODUCTIONUsually attributed to allergies or parasites (Seifert et. al Medline 2008) eosinophila is often overlooked. However hypereosinophilia (absolute eosinophil count>1.5 X 109/L on two separate exams one month apart or with pathologic confirmation) can have serious manifestations. When hypereosinophilia is associated with eosinophil-mediated organ damage or dysfunction, a hypereosinophilic syndrome (HES) exists.With an unpredictable course, eosinophilic infiltration commonly affects the skin (eczema), lung (dyspnea), &GIT (gastritis). However life-threatening damage to the CVS (myocarditis) or the CNS may occ...
Source: Blood - Category: Hematology Authors: Tags: 634. Myeloproliferative Syndromes: Clinical Source Type: research
More News: Cancer & Oncology | Leukemia | Lymphoma | Myeloma | Myocarditis